GU Oncology Now Announces Exclusive Partnership with the Uromigos

GU Oncology Now is excited to officially announce that it has expanded the content available on its collaborative and innovative digital platform for healthcare professionals treating genitourinary diseases, by partnering with the founders of the Uromigos podcasts, Drs. Thomas Powles and Brian Rini.

“This strategic alliance strengthens our ability to further develop practical, timely, and relevant clinical information to practicing physicians treating genitourinary cancer,” said Joe Palumbo, CEO of Integrated Medical Communications. “We’re very appreciative of the time and effort put forth by both our publisher Mashup Media and The Uromigos in solidifying this partnership”.

“We are so proud to be uniting with the Uromigos Podcast program,” said JC Landry, President of Mashup Media. “The clinical content and educational value this partnership provides is unparalleled. I am confident it will further foster collaboration and innovation with the common goal of increasing education and making impacts in the field of GU oncology.”

Launched in 2020, The Uromigos podcast has released over 100 episodes featuring a host of topics across GU malignancies. Each podcast features a guest expert from around the world discussing the latest data and clinical news relevant to the practical clinical care of genitourinary oncology patients. The podcast also features breaking news from key medical conferences, including the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).

“We are very excited to be able to further expand our listenership of these podcasts and broadcast to a wider audience through this partnership. By utilizing the GU Oncology Now platform, we expand upon our goal of making a scientific impact and improving patient care” said, Dr. Brian Rini.

The Uromigos podcast will premier its launch on GU Oncology Now with exclusive coverage from the ASCO 2021 Annual Meeting featuring coverage of abstracts in kidney, bladder, and prostate cancer.

About GU Oncology Now

GU Oncology Now is a print and digital platform that aims to deliver the latest news in therapeutics, conference coverage, clinical trials, and more. The print journal reaches a circulation of over 14,000, with recipients including medical oncologists, urologists, radiation oncologists, and nuclear medical radiologists who will benefit from the latest news surrounding genitourinary cancer. GU Oncology Now is owned and operated by Integrated Medical Communications (IMC) and published by Mashup Media. IMC is a medical publishing company aimed at providing the latest in healthcare news and published literature to healthcare professionals across multiple specialties. IMC promotes excellence through providing news that is fair, balanced, and accurate. IMC collaborates with societies, organizations, thought leaders, and experts to develop high-level content in both digital and print platforms.
To learn more, visit:

About The Uromigos

Thomas Powles, MBBS, MRCP, MD is a Clinical Professor of Genitourinary Oncology (HCC) at Barts Cancer Institute, UK. His research largely focuses on bladder and renal cancers. He has contributed immensely to the development of immune checkpoint inhibitors in renal cancer. Currently, he is researching redefining the treatment of patients with relapsed testis cancer, and the mechanisms of resistance to therapy in urology cancer. Follow @tompowles1

Brian Rini, MD, FASCO is the Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center, where he also serves as an Ingram Professor of Medicine. He previously worked at Cleveland Clinic as director of the Genitourinary Cancer Program. Dr. Rini was the lead investigator of the study that resulted in the Food and Drug Administration’s approval of the combination of the targeted therapy axitinib and the immunotherapy pembrolizumab. Dr. Rini also served as immediate past Chair of the Oncologic Drugs Advisory Committee (ODAC) to FDA. Follow @brian_rini

Visit the full list of Uromigos podcasts:

Leave a Reply

Your email address will not be published. Required fields are marked *

Contact us

Fill in the form below or give us a call and we'll contact you. We endeavour to answer all enquiries within 24 hours on business days.